sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models

Abstract excerpt

mRNA-based vaccines can be rapidly manufactured and have been demonstrated clinically to raise robust immune responses to COVID-19 and protect against severe COVID-19 disease. The clinical immunogenicity and efficacy of self-amplifying mRNA (sa-mRNA) vaccines have also been demonstrated, along with a longer duration of action than mRNA vaccines. However, a detailed understanding of differences between sa-mRNA and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Cell Function and Interaction
• Share to Immunotherapy and Immune Responses
• Share to Influenza Virus Research Studies